M
Michael B. Sporn
Researcher at Dartmouth College
Publications - 561
Citations - 96644
Michael B. Sporn is an academic researcher from Dartmouth College. The author has contributed to research in topics: Transforming growth factor & Transforming growth factor beta. The author has an hindex of 157, co-authored 559 publications receiving 94605 citations. Previous affiliations of Michael B. Sporn include Cornell University & Reata Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Physicochemical activation of recombinant latent transforming growth factor-beta's 1, 2, and 3.
TL;DR: The results suggest common elements in latent complex structure despite differences between the TGF-beta subtypes in pro-region primary sequence as well as a common series of sharply defined parameters for activation.
Journal ArticleDOI
Synthetic Oleanane Triterpenoids: Multifunctional Drugs with a Broad Range of Applications for Prevention and Treatment of Chronic Disease
Karen T. Liby,Michael B. Sporn +1 more
TL;DR: In these interactions, the addition of SOs to reactive cysteine residues in specific molecular targets triggers biological activity, Ultimately, SOs are multifunctional drugs that regulate the activity of entire networks.
Journal Article
Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia
Joyce O'Shaughnessy,Gary J. Kelloff,Gary Gordon,Andrew J. Dannenberg,Waun Ki Hong,Carol J. Fabian,Caroline C. Sigman,Monica M. Bertagnolli,Steven P. Stratton,Stephen Lam,William G. Nelson,Frank L. Meyskens,David S. Alberts,Michele Follen,Anil K. Rustgi,Vassiliki A. Papadimitrakopoulou,Peter T. Scardino,Adi F. Gazdar,Lee W. Wattenberg,Michael B. Sporn,Wael Sakr,Scott M. Lippman,Daniel D. Von Hoff +22 more
TL;DR: The AACR IEN Task Force recommends focusing on established precancers as the target for new agent development because of the close association between dysplasia and invasive cancer and because a convincing reduction in IEN burden provides patient benefit by reducing cancer risk and/or by decreasing the need for invasive interventions.
Journal ArticleDOI
Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors
TL;DR: It is shown that further purification of crude SGF by reverse-phase HPLC on muBondapak C18 and CN columns at pH 2 resolves it into two distinctly different polypeptides, which are called types alpha and beta transforming growth factors (TGFs).
Journal ArticleDOI
Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice.
Thomas E. Sussan,Tirumalai Rangasamy,Tirumalai Rangasamy,David J. Blake,Deepti Malhotra,Hazim El-Haddad,Djahida Bedja,Melinda S. Yates,Ponvijay Kombairaju,Masayuki Yamamoto,Karen T. Liby,Michael B. Sporn,Kathleen L. Gabrielson,Hunter C. Champion,Rubin M. Tuder,Rubin M. Tuder,Thomas W. Kensler,Shyam Biswal +17 more
TL;DR: Protection from CS-induced emphysema depended on NRF2, as Nrf2−/− mice failed to show significant reduction inAlveolar cell apoptosis and alveolar destruction after treatment with CDDO-Im, which suggests that targeting the Nrf1 pathway during the etiopathogenesis of emphySEma may represent an important approach for prophylaxis against COPD.